anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUNDFrailty significantly affects morbidity and mortality rates in the older population (age >65 years). Age-related degenerative diseases are influenced by the intestinal microbiota. However, limited research exists on alterations in the intestinal microbiota in frail older individuals, and the effectiveness of prebiotic intervention for treating frailty remains uncertain.OBJECTIVEWe sought to examine the biological characteristics of the intestinal microbiome in frail older individuals and assess changes in both frailty status and gut microbiota following intervention with a prebiotic blend consisting of inulin and oligofructose.METHODSThe study consisted of 3 components: an observational analysis with a sample size of 1,693, a cross-sectional analysis (n = 300), and a multicenter double-blind, randomized, placebo-controlled trial (n = 200). Body composition, commonly used scales, biochemical markers, intestinal microbiota, and metabolites were examined in 3 groups of older individuals (nonfrail, prefrail, and frail). Subsequently, changes in these indicators were reevaluated after a 3-month intervention using the prebiotic mixture for the prefrail and frail groups.RESULTSThe intervention utilizing a combination of prebiotics significantly improved frailty and renal function among the older population, leading to notable increases in protein levels, body fat percentage, walking speed, and grip strength. Additionally, it stimulated an elevation in gut probiotic count and induced alterations in microbial metabolite expression levels as well as corresponding metabolic pathways.CONCLUSIONSThe findings suggest a potential link between changes in the gut microbiota and frailty in older adults. Prebiotics have the potential to modify the gut microbiota and metabolome, resulting in improved frailty status and prevention of its occurrence.TRIAL REGISTRATIONClinicalTrials.gov NCT03995342.
One or more techniques and/or systems are provided for facilitating a virtual competition environment. One or more users may register for access to the virtual competition environment in order to compete in various types of activities, such as workout activities, dance activities, real-world activities, and/or virtual activities. A user may be provided with activity assignments, user created activities, and/or challenge activities between groups of users through the virtual competition environment (e.g., the virtual competition environment may be accessible through a website, a mobile app, etc.). The user may upload activity results for activity assignments, which may be evaluated and/or ranked against how other users performed such activity assignments. The user may register as a judge in order to evaluate and/or rank activity results (e.g., evaluate videos of users performing an activity). Users and/or judges may be rewarded for participating in activities and/or judging activities.
Delayed loss of residual acoustic hearing after cochlear implantation is a common but poorly understood phenomenon due to the scarcity of relevant temporal bone tissues. Prior histopathological analysis of one case of post-implantation hearing loss suggested there were no interaural differences in hair cell or neural degeneration to explain the profound loss of low-frequency hearing on the implanted side (Quesnel et al., 2016) and attributed the threshold elevation to neo-ossification and fibrosis around the implant. Here we re-evaluated the histopathology in this case, applying immunostaining and improved microscopic techniques for differentiating surviving hair cells from supporting cells. The new analysis revealed dramatic interaural differences, with a > 80 % loss of inner hair cells in the cochlear apex on the implanted side, which can account for the post-implantation loss of residual hearing. Apical degeneration of the stria further contributed to threshold elevation on the implanted side. In contrast, spiral ganglion cell survival was reduced in the region of the electrode on the implanted side, but apical counts in the two ears were similar to that seen in age-matched unimplanted control ears. Almost none of the surviving auditory neurons retained peripheral axons throughout the basal half of the cochlea. Relevance to cochlear implant performance is discussed.
UNLABELLED: Littre's hernia is an extremely rare type of hernia which has Meckel's diverticulum as its content. A 63-year-old male, presented to the emergency department with chief complaints of swelling and pain around the umbilicus. The patient was diagnosed with an incarcerated umbilical hernia. Following the emergency laparotomy, the intraoperative finding depicted an umbilical Littre's hernia. The patient underwent open Meckel's diverticulectomy with mesh repair. Preoperative diagnosis of Littre's hernia is unlikely due to its low incidence and lack of specific radiological and clinical findings, but the role of computed tomography scan and ultrasound are important in differentiating between strangulated or incarcerated bowel and omentum and in guiding the urgency of operative management.
KEYWORDS: case reports; hernia; Meckel diverticulum.
Participants were randomized to receive an arm. In this arm, participants received placebo capsule and were asked to consume at 40 mg/kg (1-2 capsule) within 15-30 min after breakfast. Consumption was taken at participants' dwelling.
BACKGROUND: Burnout syndrome (BS) among healthcare professionals in Peru demands immediate attention. Consequently, there is a need for a validated and standardized instrument to measure and address it effectively. This study aimed to determine the psychometric properties of the Maslach Burnout Inventory (MBI) among healthcare professionals in the Ancash region of Peru.
METHODS: Using an instrumental design, this study included 303 subjects of both sexes (77.56% women), ranging in age from 22 to 68 years (M = 44.46, SD = 12.25), selected via purposive non-probability sampling. Appropriate content validity, internal structure validity, and item internal consistency were achieved through confirmatory factor analysis, and discriminant validity for the three dimensions was obtained. Evidence of convergent validity was found for the Emotional Exhaustion (EE) and Personal Accomplishment (PA) dimensions, with reliability values (ω > .75).
RESULTS: The EE and PA dimensions exhibited acceptable levels of reliability (ω and α > .80). However, the Depersonalization (DP) dimension demonstrated significantly lower reliability (α < .60 and ω < .50).
CONCLUSIONS: A correlated three-factor model was confirmed, with most items presenting satisfactory factor loadings and inter-item correlations. Nonetheless, convergent validity was not confirmed for the DP dimension.
1354204 Cyanoacrylate cement compositions JOHNSON & JOHNSON 10 June 1971 [11 June 1970] 41612/72 Divided out of 1343790 Heading C3P Cement compositions comprise a polymerizable ester of alpha-cyanoacrylic acid having the formula (I) where R is C 1 -C 16  alkyl, cyclohexyl or phenyl, and 1-4 parts by weight (per part by weight of the ester) of a finely divided filler of which 25-75% by weight has particle sizes in the range of 40-50 microns and 75-25% by weight has particle sizes in the range of 90-100 microns. Suitable fillers include fused silica, quartz, alumina and finely divided polyethylene, and a minor proportion (less than 25% by weight) of the filler may have particle sizes outside the ranges specified above. The compositions may also contain an amine activator. In one embodiment the filler is pretreated with triphenylsilane or a non-catalytic trialkoxysilyl compound and the amine activator is superimposed thereon. The cement compositions are useful in dental applications and, for this purpose, may sometimes be tinted, e.g. with finely divided carbon. They are also useful for filling or bonding a variety of materials, e.g. ceramics, glass, metal, wood and rubber.
OBJECTIVES: I. Determine variation in indium In 111 labeled 2IT-BAD monoclonal antibody 170 (111In-2IT-BAD-m170) pharmacokinetics before and with each therapy in patients with metastatic breast cancer. II. Determine each therapeutic dose of yttrium Y 90 labeled 2IT-BAD monoclonal antibody 170 (90Y-2IT-BAD-m170) based on the calculated radiation dosimetry for normal nonmarrow tissues from the pharmacokinetic study with 111In-2IT-BAD-m170 performed prior to each therapy course in these patients. III. Determine the maximum tolerated, nonmarrow, normal tissue dose (MTNTD) of 90Y-2IT-BAD-m170 for these patients when up to 3 courses with cyclosporine plus autologous peripheral stem cell support are given every 3 months. IV. Evaluate the safety of and tumor response to 111In/90Y-2IT-BAD-m170 therapy with cyclosporine and autologous peripheral stem cells at the MTNTD in these patients.

OUTLINE: This is a dose escalation study of yttrium Y 90 labeled 2IT-BAD monoclonal antibody 170 (90Y-2IT-BAD-m170). Patients are stratified according to risk based on prior therapy (standard combined chemotherapy vs standard and high dose combined chemotherapy with bone marrow transplant or stem cell support). All patients receive subcutaneous filgrastim (G-CSF) during stem cell collection. Beginning 3 to 5 days after starting G-CSF, patients undergo apheresis either daily or every other day for 4 to 8 procedures. Patients receive oral cyclosporine twice daily, starting on day 1, for up to 2 weeks. On day 4, patients receive nonlabeled 2IT-BAD monoclonal antibody m170 IV over 10-15 minutes, followed 15 minutes later by indium In 111 labeled 2IT-BAD monoclonal antibody 170 (111In-2IT-BAD-m170) IV over 10-15 minutes. Patients then undergo dosimetry imaging immediately, again 3 hours later, and then on days 1-4 and day 7 postinjection. Patients receive nonlabeled monoclonal antibody IV over 10-15 minutes, followed 15 minutes later by In 111/Y 90 labeled 2IT-BAD monoclonal antibody 170 (111In/90Y-2IT-BAD-m170) IV over 10-15 minutes, then undergo imaging as in pretherapy. Patients also receive cyclosporine, administered as in pretherapy, for a total of 35 days, plus autologous stem cell support followed by G-CSF after each course. Cohorts of 3-9 patients receive escalating doses of 111In/90Y-2IT-BAD-m170. Patients proceed to the next dose level if 3 or more patients in the same or higher risk group have not reached the maximum tolerated, nonmarrow, normal tissue dose (MTNTD) at least 3 months after the second course of therapy. Therapy repeats every 3 months for 3 courses.

PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study.
We set out to examine in an observational study characteristics of type 1 diabetes at the time of diagnosis among paediatric patients carrying the protective HLA class II DQB1*06:02 allele. We compared characteristics of type 1 diabetes among 5530 Finnish children aged 0-14 years diagnosed between 2003 and 2018. Seventy-five children with type 1 diabetes carried the DQB1*06:02 allele. The carriers of DQB1*06:02 allele were compared to all children with type 1 diabetes without this allele and those with a high-risk genotype. We also analysed, how does the genotype of a high-risk haplotype paired with DQB1*06:02 affect the phenotype of patients with newly diagnosed type 1 diabetes. Carriers of the DQB1*06:02 allele were diagnosed at an older age than those with any other HLA class II genotype (p = 0.003) or the high-risk genotype (p < 0.001). After adjusting the results for age and sex, no significant differences in clinical markers were observed. Glutamic acid decarboxylase autoantibody (GADA) levels were higher among carriers of DQB1*06:02 when compared to those with other genotypes (p = 0.033). Having a high-risk haplotype paired with DQB1*06:02-positive haplotype was associated with higher levels of islet antigen 2 autoantibodies (IA-2A) (p < 0.001) and somewhat shorter duration of symptoms (p = 0.043). The association between the protective DQB1*06:02 allele and an older age at diagnosis as well as higher levels of GADA at diagnosis of type 1 diabetes was confirmed. The effects of the DQB1*06:02-positive haplotype seem to dominate when paired with a high-risk haplotype.
INTRODUCTION: COPD has become more prevalent among women, revealing a specific feminine phenotype. Women experience greater dyspnea and a more impaired quality of life. The main objective of this study was to assess the effect of gender on dyspnea during a pulmonary rehabilitation program (PRP).
METHODS: Retrospective study including COPD patients having participated in PRPs. The following data were analyzed according to gender before and after a PRP: dyspnea, quality of life, anxiety and depression, exercise capacity, muscle function (quadriceps and inspiratory muscles).
RESULTS: More than 500 patients (252 men and 252 women) were included. We did not find a significant effect of gender on the evolution of dyspnea, anxiety or depressive disorders, exercise capacity, inspiratory muscle strength, or overall quality of life score. That said, we found a possible effect on the sub-scores of the quality of life questionnaire, and regarding quadriceps strength. All criteria improved during the program in both groups.
CONCLUSIONS: During a PRP, gender does not impact the evolution of dyspnea. While women may nonetheless benefit to a greater extent in terms of quality of life sub-scores (impact, activities, symptoms) and quadriceps strength, these results still require confirmation.
Patients in the cognitive REM condition attended up to 25 h of training in small groups over 4-6 weeks based on the approach to cognitive remediation described by Wexler and Bell (2005). Patients performed tasks designed to train attention and memory from the battery available within a computerized software package (CogPack Marker Software). This training protocol has been shown to improve memory and executive functioning in patients with schizophrenia (Sartory et al, 2005) and tasks chosen were designed to produce improved working memory and attention capacity in the treated group. In addition, patients in the REM group trained on the word N-back one to two times a week and on N-back tasks using a variety of other stimuli (such as faces) one to two times a week to support the generalization of working memory improvements.
Neurofeedback training: self-administered at home for 3 months. 3-5 sessions per week initially, then at least once a week. Each session consists of 5-6 blocks of 5 minute training.
Disclosed are injection molded devices including microneedles on a substrate base. The microneedles may include a plurality of nano-sized structures fabricated thereon. The molds used to form the microneedles are assembled from a plurality of mold segments, each defining portions of the microneedles. Upon assembly of the multiple mold segments, microneedle negative cavities are formed. The molds may be used in an injection molding process to form microneedle arrays. Devices may be utilized for interacting with a component of the dermal connective tissue.
FIELD: mdicine, oncology, immunology. SUBSTANCE: invention relates to the treatment of patients with B-cellular lymphoma. Invention proposes a new immunologically active chimeric antibody - anti-C20 among them an antibody labeled with radioisotope and also a hybridoma producing an antibody showing specificity with respect to C20-antigen. Method of treatment involves the administration of indicated antibody preparations by three stages using different therapeutically effective amounts of these antibodies. EFFECT: enhanced specificity of effect on malignant cells. 15 cl, 3 tbl
The intricate interrelationships between visual acuity (VA) and stereopsis depend on an array of factors, incorporating the nature of vision impairment, its manifestation (monocular versus binocular), and the classification of stereopsis test symbols used. The objectives of this study were to methodically dissect these multifaceted interactions by simulating a diverse range of vision loss conditions. Thirty medical students with normal vision were subjected to simulated vision loss through opacification and blurring methodologies. Stereopsis was assessed at a distance using both contour-based and random-dot-based symbols under equal binocular and varied monocular VA conditions. In this study, opacification consistently affected stereopsis more than blurring at equivalent VA reductions. However, this difference was absent in contour-based symbols under binocular vision impairment conditions. Significant differences in stereopsis emerged between monocular and binocular vision within the opacification contour-based groups. These differences were less evident in the opacification and blurring groups using random-dot-based patterns. In terms of symbols, the contour-based test demonstrated superior results to the random-dot-based test, particularly under decreased VA. In sum, the method of VA reduction and the choice of stereogram significantly impact distance stereopsis outcomes. This understanding can guide clinical assessments of stereopsis in individuals with varying visual impairments.
The present invention relates to intracellular receptors, and methods for the modulation of transcription using same. More particularly, the invention relates to the Nur family of nuclear receptors. In general aspects, the present invention relates to the idenfication of a physiologically relevant response element (RE) for Nur family members, an ER-10 element, as well as to the idenfication of the type of protein-protein interactions of Nur family member, enabling their specific interaction with this RE-10 and their modulation of transcription at physiologically relevant sites. The invention further relates to methods for modulating processes mediated by such nuclear receptors. In addition, the invention relates to oligonucleotide sequences that bind regulatory proteins that affect transcription, such as the Nur family of nuclear receptors, to DNA constructs comprising the oligonucleotide sequences, cells transfected with the DNA constructs, to methods of using same to provide for the controlled expression of heterologous genes, and for the detection and recovery of new regulatory proteins. The present invention further provides bioassays for the identification of compounds as potential agonists or antagonists of transcription by the Nur family of nuclear receptors. Moreover, the invention relates to the dissection of protein-protein interactions or ligand-protein interactions involved in the modulation of transcription by the Nur family of nuclear receptors.
PURPOSE:To extract intercellular matrix, by perfusing an animal organ with a solution of a protein denaturation agent. CONSTITUTION:An animal organ (e.g. fresh brain, lung, liver, heart, kidney, large intestine, small intestine, stomach, uterus, blood vessel, etc. of cattle, horse, goat, sheep, pig, etc.) is depleted, and washed by introducing a preperfusate such as physiological saline water, plasma substitute, etc. into the blood vessel at a definite rate. A protein denaturation agent such as urea, guanidine hydrochloride, p-aminosalicylic acid, etc. is introduced into the blood vessel to effect the perfusation of the organs and obtain an extracted liquid containing the intercellular matrix component. the extract is filtered with a millipore filter to remove the cell fragments, etc., and subjected to the dialysis and gel-filtration to remove the low-molecular substances such as the protein- denaturation agent. The roughly purified intercellular matrix component prepared by the process is useful as an agent to facilitate the in vitro cultivation of epithelial cells, a remedy for lesion, or a part of the material constituting artifical organs.
The invention relates to a cyclocasein-isoleucyl-leucyl-chromo-threonine (Tyr-Ile-Leu-Trp-Thr cyclopeptide) with antifungal activity and free radical scavenging activity and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. The cycloparaffin-isoleu-leu-tryptophan-threonine peptide is a pentadecentricular pentapeptide formed by connecting tyrosine, isoleucine, leucine, tryptophan and threonine by amido bonds. This is a new compound and has not been reported in the literature. The compound can be obtained by culturing Rana chensinensis mould, and extracting and separating. The pure product of Cyclocasein-isoleum-leum-cromogen-threonine is white powder, and has half scavenging concentration (DC) for DPPH free radical  50  ) Comprises the following steps: 0.82mg/mL, and the diameter of the zone of inhibition of Streptococcum albopictus at a concentration of 200. mu.g/mL is 11.36 mm. The compound has the potential of preparing antibacterial drugs and antioxidant and anti-aging health care products.
PURPOSE:To produce the titled slow-releasing drug preparation, by adding a drug such as growth regulator, osteometabolism-relating agent, thromobolytic agent, immunorgulator, anti-inflammatory agent, etc., and albumin to a silicone elastomer and using the elastomer as a matrix or using a membrane of the elastomer as a drug container. CONSTITUTION:A silicone elastomer containing <=50wt% drug and <=50wt% albumin is used as a matrix or a membrane of the elastomer is used as a drug container to obtain the objective slow-releasing drug preparation. The compounding of a silicone elastomer with a drug together with albumin attains the stabilization and slow releasing of the drug. Highest effect can be achieved when the drug is a polymeric drug having a molecular weight of 1,000-500,000 (e.g. peptide, protein, polysaccharide, etc.). The silicone elastomer is preferably a cold-curing elastomer such as dimethylpolysiloxane of formula (n is 100-5,000; R is CH3, OH or vinyl).
The variability in response to conventional prostate cancer (PC) therapies, coupled with the emergent issue of drug resistance, underscores the critical need for innovative treatment strategies. Aerobic physical exercise reduced incidence of several cancers, but the mechanism underlying these effects associated the nanoemulsion not fully understood. The application of a lipid nanoemulsion (LDE) delivery system for docetaxel (DTX), showing marked enhancement in therapeutic efficacy when combined with aerobic physical exercise. This novel intervention potentiates the antitumor activity of LDE-delivered DTX by augmenting nanoparticle internalization and inducing cell cycle arrest. Our findings reveal that this synergistic treatment not only significantly reduces prostate weight and mitigates adenocarcinoma proliferation but also attenuates anti-apoptotic BCL-2 protein expression. Concurrently, it elevates pro-apoptotic proteins and diminishes inflammatory markers. Metabolic profiling of the combined therapy group disclosed additional benefits, such as reduced lipid and plasma glucose levels. Collectively, our data illuminate the profound impact of integrating LDE-mediated DTX delivery with structured physical exercise, which together spearhead a dual-front assault on PC. This multimodal approach heralds a new paradigm in PC management, accentuating the promise of combined pharmacological and non-pharmacological interventions to elevate tumor suppressor protein activity and refine patient outcomes.